|
Tourmaline Bio Inc (NASDAQ: TRML) |
|
Tourmaline Bio Inc
TRML's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Tourmaline Bio Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.3 %
Tourmaline Bio Inc net loss increased from $-7 millions, to $-20 millions in III. Quarter 2024,
• More on TRML's Growth
|
|
Tourmaline Bio Inc realized a net loss in trailing twelve months.
Tourmaline Bio Inc realized cash reduction of $ -1.03 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.63.
• More on TRML's Valuation
|
|
|
|
|
Tourmaline Bio Inc realized net loss in trailing twelve months.
Tourmaline Bio Inc realized cash outflow of $ -1.03per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.63.
Tourmaline Bio Inc Price to Book Ratio is at 1.15 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02
• More on TRML's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com